Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group

✍ Scribed by E Briasoulis; N Pavlidis; C Terret; J Bauer; W Fiedler; P Schöffski; J-L Raoul; D Hess; R Selvais; D Lacombe; P Bachmann; P Fumoleau

• Book ID: 117660211
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 218 KB
• Volume: 39
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(03)00629-4